Skip to main content
Debasish Tripathy, MD, Oncology, Houston, TX

DebasishTripathyMD

Oncology Houston, TX

Professor of Medicine, University SC School of Medicine

Dr. Tripathy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Tripathy's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd

    Houston, TX 77030
    Phone+1 713-792-6161
    Fax+1 713-563-0903

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1989 - 1991
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1985 - 1989
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1985

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2023 - 2026
  • MS State Medical License
    MS State Medical License 2023 - 2025
  • OK State Medical License
    OK State Medical License 2020 - 2025
  • TN State Medical License
    TN State Medical License 2023 - 2025
  • TX State Medical License
    TX State Medical License 2002 - 2025
  • WA State Medical License
    WA State Medical License 2023 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology
  • Join now to see all

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2006, 2010-2014
  • Top Doctors:LA Area Castle Connolly, 2013
  • America's Top Doctors for Cancer Castle Connolly, 2005-2007, 2009-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain ... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Giving HRT to Breast Cancer Survivors DOES NOT Raise Risk of Recurrence, Study Suggests
    Giving HRT to Breast Cancer Survivors DOES NOT Raise Risk of Recurrence, Study SuggestsJuly 20th, 2022
  • New Treatments Changing the Lives of People with Breast Cancer, and More Promise Lies Ahead
    New Treatments Changing the Lives of People with Breast Cancer, and More Promise Lies AheadOctober 8th, 2021
  • Physicians’ Education Resource® Presents Three Satellite Symposia at the 36th Annual Miami Breast Cancer Conference®
    Physicians’ Education Resource® Presents Three Satellite Symposia at the 36th Annual Miami Breast Cancer Conference®February 25th, 2019
  • Join now to see all

Grant Support

  • Expression Analysis Of ERBB Receptor Targeted TherapiesNational Cancer Institute2001–2002
  • Core--Clinical CoreNational Cancer Institute1995–2002